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ABSTRACT 
 
 
            Fifty patients with breast cancer of various clinical stages from 
different parts of Sudan were selected randomly for this study . The 
patients  were divided into two equal groups , one consists of patients 
treated by surgery only , the other patients were treated by surgery and 
other methods of treatment . Serum total cholesterol , cholesterol 
fractions , and tumor necrosis factor–alpha were determined in breast 
cancer patients. The results  were compared with  randomly selected 
apperantly healthy females . It was observed that , there was a highly 
significant decrease in serum total cholesterol and low density lipoprotein 
cholesterol . Whereas the high  density lipoprotein cholesterol was found 
to be non significant . On the  other hand serum tumor necrosis factor –
alpha increased and this was highly significant in all patients compared to 
the control .                                                                                                    
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  ﻣﻠﺨﺺ اﻟﺒﺤﺚ
  
 ﻣﺨﺘﻠѧѧﻒ اﻻﻃѧѧﻮار اﻻآﻠﻴﻨﺒﻜﺒѧѧﺔ  ﻓѧѧﻰﺧﻤѧѧﺴﻮن ﻣﺮﻳѧѧﻀﺎ ﺑѧѧﻮرم اﻟﺜѧѧﺪى اﻟﺨﺒﻴѧѧﺚ ﻣѧѧﻦ اﻻﻧѧѧﺎث 
 اﻟﻤﺮﺿѧﻰ ﻗѧﺴﻤﻮا اﻟѧﻰ .ة  اﻟﺪراﺳﺔ  ﺬان ﻟﻬ  ﻣﻦ ﻣﺨﺘﻠﻒ اﻧﺤﺎء اﻟﺴﻮد اﺋﻴﺎاﺧﺘﺒﺮوا ﻋﺸﻮ 
ﻣﺠﻤﻮﻋﺘﻴﻦ ﻣﺘﺴﺎوﺗﻴﻦ ﻣﺠﻤﻮﻋѧﺔ ﺗﺤﺘѧﻮى ﻋﻠѧﻰ ﻣﺮﺿѧﻰ ﺗѧﻢ ﻋﻼﺟﻬѧﻢ ﺟﺮاﺣﻴѧﺎ و اﺧѧﺮى 
ﻟѧﺴﺘﺮول ﻮاﻟﻜ. ﺗﺤﺘѧﻮى ﻋﻠѧﻰ ﻣﺮﺿѧﻰ ﺗѧﻢ ﻋﻼﺟﻬѧﻢ ﺟﺮاﺣﻴѧﺎ  وﺑﻄѧﺮق ﻋﻼﺟﻴѧﺔ  اﺧѧﺮى 
ﻢ ﻟﺴﺘﺮول اﻟﺒﺮوﺗﻴﻨﺎت اﻟﺪهﻨﻴﺔ و ﻋﺎﻣﻞ اﻟѧﻮرم اﻟﻨﺨѧﺮ ﻓﺤѧﺼﺖ ﻟﻠﻤﺮﺿѧﻰ ﻓѧﻰ اﻟѧﺪم ﺛѧ ﻮوآ
ﻟѧѧѧѧﺴﺘﺮول  ﻮ ﻟѧѧѧѧﻮﺣﻆ اﻧﺨﻔѧѧѧѧﺎض ﻓىﻜ.ﻗﻮرﻧѧѧѧѧﺖ ﺑﻤﺠﻤﻮﻋѧѧѧѧﺔ  ﻣﻤﺎﺛﻠѧѧѧѧﺔ ﻣѧѧѧѧﻦ اﻻﺻѧѧѧѧﺤﺎء 
ﻟѧﺴﺘﺮول اﻟﺒѧﺮوﺗﻴﻦ اﻟѧﺪهﻨﻲ ﻮآ ﻟﺴﺘﺮول اﻟﺒﺮوﺗﻴﻦ اﻟﺪهﻨﻲ اﻟﻤѧﻨﺨﻔﺾ اﻟﻜﺜﺎﻓѧﺔ ﺑﻴﻨﻤѧﺎ ﻮوآ
 ﻓﻰ   ﻋﺎﻣﻞ  ﻣﻌﻨﻮى   و ﻣﻦ ﺟﻬﺔ اﺧﺮى وﺟﺪ ارﺗﻔﺎع .اﻟﻤﺮﺗﻔﻊ  اﻟﻜﺜﺎﻓﺔ ﻻ ﻳﻮﺟﺪ ﺑﻪ ﺗﻐﻴﺮ 
  .ﺛﻠﺔ ﻣﻦ اﻻﺻﺤﺎ ء اﻟﻮرم اﻟﻨﺨﺮ ﻓﻰ ﺟﻤﻴﻊ اﻟﻤﺮﺿﻰ ﻣﻘﺎرﻧﺔ ﺑﻤﺠﻤﻮﻋﺔ  ﻣﻤﺎ
  
  
  
  
  
  
  
  
  
  
 
 1
Introduction 
 
         Tumor is an abnomal mass of tissue the growth of which exceeds 
and is unco-ordinated with that of the tissues, and persists in the same 
excessive manner after cessation of the stimuli which evoked the change . 
Tumors are divided into two classes , benign and malignant according to 
mode  and rate of growth , histological features , and clinical effects  
(Roderick et al,2001). Cancer cells are  characterized by three properties ; 
including diminished or unrestrained control of growth ; invation of local  
tissues ; and spread or metastasis to other parts of the body by lymphatics 
and blood vessels where they give rise to secondary tumors (Greider , 
1998) . There are a number of specific tumor  markers which are found in 
serum and useful in diagnosis ,  such as α – fetoprotein , human chorionic 
gonadotrophin , and  β - prostate – specific antigen  (PSA) (Kumar and 
Clark , 1998 ) .  
            Breast cancer is the cancer of the glandular breast tissue. 
Worldwide is the fifth most common cause of cancer death , affects one 
in eight women during their lives (Wikipedia , 2007) . No one knows why 
some women get breast cancer, but there  is a number of risk factors 
including age  (the chance of getting cancer rises as a women gets older) 
genes , (there are two genes, BRCA1 and BRCA2, that greatly increase 
the risk) being overweight , and drinking alcohol . There are five stages 
of breast cancer included stage - 0 is carcinoma in situ , stage - i is an 
early stage of invasive cancer, stage - ii tumor great than 5cm spread or 
not to lymph nodes, stage- iii tumor smaller than 5cm penetrated out side 
the breast to skin of breast or chest wall , and stage - iv is distant 
metastatic cancer (Medicine . net , 2007) . 
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        The change in lipid profile have long been associated  with cancer 
because lipids play a key role in maintenance of cell integrity  (Patel  et 
al,  2004) . In human , cholesterol metabolism , its production , in the 
body has been extensively studied mainly in relation to the atherosclerotic 
process . In   the last years, cholesterol metabolism , has begun to being 
questioned also in cancer . The  mevalonate pathway is a sequence of 
enzymatic reactions leading to farnesyl pyrophosphate (-PP), which is the 
common substrate for the biosynthesis of cholesterol, as well as for 
nonsterol isoprenoid compounds that are vital for diverse cellular 
function . It is unrivaled in nature for the chemical diversity of the 
compounds it produces, most of which are rate limiting for cellular 
growth and have regulatory functions in cell proliferation . As an 
example, isopentenyl adenine is involved in DNA synthesis, dolichol is 
an important intermediate in protein glycosylation, and cholesterol is a 
constitutive membrane component. Ubiquinone is a membrane bound 
lipid participating in redox reactions necessary for ATP synthesis by 
membrane electron transport and an antioxidant protecting the cell 
membranes from oxidative damage . A novel critical role for this classic 
pathway emerged in recent years, due to the requirement of farnesyl-PP 
and geranyl-geranyl-PP in isoprenylation of various G proteins, most 
notable of which is the product of the Ras gene,  p21,  a key transducer of 
mitogenic signals . Mutations that constitutively activate Ras are found in 
about 30% of all human cancer . Finally,  an emerging theme that tightly 
links mevalonate pathway to cell proliferation is the key role that 
cholesterol plays in the maintenance of microdomains in cell membranes, 
termed raft or caveolae, that are sites where signaling molecules involved 
in cell division are concentrated (Sandra  and  Alessandra ,2004) . 
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              Tumor necrosis factor-α is a cytostatic compound for avariety of 
human cancer cells . Authors found that the cytostatic effect of  TNF-α on 
cancer cell line , was concomitant with arrest these cells in the G0/G1 
phase of the cell-cycle (Masaaki et al,1997) . Serum concentration of 
TNF-α   has been found to be increased in the circulation of patients with 
malignancy . The precise role of increase  of TNF-production in the 
development of breast cancer , however,is unclear . It  is also  known that 
TNF involved in cell death  (which occurs in normal breast tissue,but 
fails to occur in breast cancer)  (Wei-Jen  et al,1997) . 
       The aim of this work is to evaluate alterations of the level of serum 
cholesterol , lipoproteins cholesterol , and tumor necrosis factor in breast 
cancer of women and their probable role in carcinogenesis . Such  study 
is very rare if found  in the Sudan . The programme of this study tended 
to investigate total cholesterol ,  LDL-C , HDL-C , and TNF-α  in serum , 
choosing cases of breast cancer randomly from different parts of Sudan . 
Cancer stages , age group , parity , and method of treatment , were 
undertaken in consideration for this study . 
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Chapter One  
Literatue Review 
 
1 .1 Cholesterol 
  
       Cholesterol is an amphipathic lipid  (Robert et al , 1999) . It is sterol 
that related to other sterols and is contained in many food , such as diary products 
and meat fats (Jeremy , 2006) . Cholesterol is soft , waxy substance that present 
in all parts of the body , including the nervous system , skin , muscle , liver , 
intestines   , and heart  (William ,1989 ) .                                                                   
1 .1. 2 Cholesterol  metabolism  
 
      Cholesterol controls physical properties of the membrane which are 
important for function of  membrane proteins such as receptors  and transporters , 
and it is precursor of steroid hormones , vitamin D , and bile acids , which are 
essential   for digestion cholesterol that taken up from there to cells  in the 
periphery( recall  that chlomicrons by pass the liver )   , or  redistributed to other 
lipoprotein species (Palmer , 2006) . Both dietary cholesterol and that synthesized 
denovo  are transported through the circulation as particles including low density 
lipoprotein (LDL) . and high density lipoprotein (HDL) (Mahley and Innerarity, 
1983) . The synthesis and utilization  of cholesterol must be tighty regulated in 
order to prevent over-accumlation and abnormal deposition within the body 
(Spady and Wollett, 1993) . Excess cholesterol can lead to atherosclerosis , 
cardiovascular disease , stroke in wesretn countries , this leading cause of death 
being more common than all  cancers  (Gray , 1974) .                                              
1. 1 .3  Biosynthesis of cholesterol 
  
         Cholesterol is steroid alcohol with 27 corbon atoms that are arranged in 
tetracyclical perhydrocyclopentanophenanthrene skeleton  (Carl et al , 2001) as 
illustrated in figure (1) . the biosynthesis of cholesterol as shown in figure (2) 
occurs in the liver in many steps including the following :   
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1- Acetyl- COA are  converted to 3- hydroxyl – 3methylglutaryl –COA 
(HMG-COA) .   
2- (HMG-COA) Iis converted to mevalonate .  
3- Mevalonate is converted to the isoprene based molecule . 
isopentenylpyrophosphate (IPP) , with concominant loss of CO2 .  
4- Isopentenylpyrophosphate (IPP) is converted  to geranylpyrophosphate 
5- Geranylpyrophosphate is converted  to farenylpyrophosphate . 
6- Farenylpyrophosphate is converted  to  squalene . 
7- Squalene is converted  to lansterol , and lansterol then converted  to 
cholesterol(Micheal ,2000) . 
      The   biosynthesis of cholesterol is regulated by both allosteric control 
of enzyme activity and by enzyme induction . The rate-limiting step in 
cholesterol synthesis is  reduction of HMG-COA to mevalonate by 
enzyme HMG-COA reductase the primary target of regulation . After 
cholesterol is  synthesized it either converted  to bile acids for use in the 
digestive process or coupled to fatty acids to form cholesterol esters 
(Pamela , 2005). Cholesterol esters are packed together with triglycerides 
into very- low density lipoprotein  (VLDL) to transported in the blood 
stream to other tissues . As the VLDL circulates in the blood stream the 
triglycerides are taken up by muscle and adipose tissue cells , where they 
are hydrolyzed by lipoprotein lipase to fatty acids and glycerol . 
Thereafter , will be converted  to cholesterol rich intermediate- density 
lipoprotein ( IDL) and (LDL) (Russel , 1992) . In side cell , cholesterol 
incorporated into the various membrane inside or surrounding  the cell or 
stored as cholesterol esters droplets.Less than half of cholesterol is 
derived from denovo . Biosynthesis in the liver accounts for 
approximately 10% and in intestines approximately 15% the accounts 
produced each day (Pamela , 2005) .                                                           
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Figure (1) :  Structure of cholesterol    
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Figure (2) :  Pathways of biosynthesis of cholesterol 
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          +                  -----→ HMG-CoA ------------→ Mevalonate  
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1.1.3 Excretion of cholesterol  
        Cholesterol can be eliminated from the body either by convertion  to 
bile salts or by secretion into bile . Intestinal bacteria can reduce to 
coprostanol and cholestanol which together with cholesterol made up the 
bulk of neutral fecal sterols (Pamela , 2005) . About 1g of Cholesterol is  
eliminated from the body per day . Approximately half is excreted in the 
faeces after convertion to bile acids(Carl et al ,2001) .The bile salts are 
strongly amphipathic and act as detergents to help emulsification of lipid . 
About 30 g  of bile salts are secreted by the bile duct every day (Mendez et 
al , 1991) . Almost all of this amount is actively reabsorbed so that only 
about  1g  of bile salts and cholesterol are lost  each day in the faeses .  The 
reabsorbed bile salts and cholesterol are transported back to the liver buond 
to albmin and are recycled . This secretion and  reabsorbed constitutes the 
enteroheptic circulation (Micheal ,2000) .    
1. 1.4  Cholesterol and breast cancer  
        Some of the biochemical characteristics of human breast cancer were 
defined by examining the activities of several specific enzymes associated 
with carbohydrate, lipid, and amino acid metabolism in forty-nine samples of 
infiltrating ductal carcinoma of the breast. In addition, the levels of RNA, 
DNA, cholesterol, free fatty acids, and triglycerides were determined . 
Samples of normal breast tissue and fibrocystic disease of the breast were 
also analyzed for the same parameters.Compared with normal breast tissue, 
the activities of pyruvate kinase, glucose-6-phosphatedehydrogenase, 
isocitrate dehydrogenase, phosphoglucomutase, glutamate dehydrogenase, 
and hexokinase in the carcinomas were elevated 10- to 30-fold, when 
enzyme activity was expressed per 100 mg of tissue weight, or from 2- to 8-
fold, when enzyme activity was expressed per mg DNA. RNA and DNA 
levels were increased in neoplastic tissues, as were those of cholesterol and 
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free fatty acids, whereas triglyceride levels were significantly reduced in the 
tumors. In fibrocystic disease, only the activity of phosphoglucomutase, 
expressed per mg DNA, was higher than in normal breast tissue . Significant 
correlations between pairs of biochemical parameters were found ; some 
were common to all tissues investigated, whereas others were present only in 
carcinomas. No differences in the biochemical profile of neoplastic tissues 
were attributable to either the menopausal status of the patient or to the 
presence of metastases . Thus, certain unique biochemical changes were 
associated with frank carcinoma and, in this limited study, we were able to 
identify a tissue sample as cancer or noncancer on the basis of the observed 
biochemical profile (Russel et al, 2004). Other studies have revealed that 
cells possess two cholesterol-sensors: (a) Receptor-C_k which senses the 
extracellular cholesterol and initiates signalling pathway responsible for the 
regulation of genes involved in the cell cycle, cell death, cellular cholesterol 
homeostasis and cytokines including IL-6; (b) LxR which senses 
intracellular oxysterols and controls genes involved in cell death, cellular 
cholesterol homeostasis and cytokine IL-8. These cholesterol sensors define 
the molecular mechanism responsible for cholesterol-depended regulation of 
cellular synthesis and secretion of cytokines (IL-6, IL-8) within arterial wall. 
On the basis of this mechanism, presence of cholesterol and its oxy-
derivative in the modified LDL will result in transient activation/deactivation 
of Receptor-C_k-dependent genes which will give rise to repeated cycles of 
growth coupled with apoptosis leading to a situation where apoptotic-
deficient cells in the arterial wall, would be selected resulting in their 
accumulation and formation of oligoclonal atherosclerotic plaque ( Kaul , 
2001) . Although many studies have shown an increased risk of death from 
cancer in subjects with low plasma cholesterol concentrations, the underlying 
mechanism between low blood cholesterol and cancer is unclear. 
Apolipoprotein E is a central regulatory protein in cholesterol metabolism, 
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and recent studies have shown that apolipoprotein E is a potent inhibitor of 
angiogenesis and tumour cell growth. Apolipoprotein E has three common 
isoforms, E2, E3, and E4, which are coded by the alleles e2, e3 and e4, 
respectively. The e4 allele is associated with high serum total and low 
density lipoprotein cholesterol concentrations. Recently, it was suggested 
that the apolipoprotein E e4 allele may protect Authors hypothezised that the 
apolipoprotein E polymorphism could also be associated with other cancer 
types (Niemi et al ,2000) . An important factor which determines the 
movement of cholesterol in and out of the cells is the free cholesterol 
(FC)/esterified cholesterol (EC) ratio in the plasma. Although this ratio has 
been shown to be increased in several types of malignancies in humans as 
well as experimental animals, it is not known whether such an abnormality is 
found in breast cancer patients. Furthermore, the reasons for such an increase 
in cancer patients are unknown. We studied the plasma lipid composition 
and the activity of lecithin-cholesterol acyltransferase (LCAT), the enzyme 
responsible for the formation of most of EC in human plasma, in 12 women 
with breast cancer and 9 agematched control women. The plasma EC 
concentration was found to be significantly decreased in cancer patients, 
whereas the FC concentration was unchanged, leading to increased FC/EC 
ratios (P<0.05). The concentration of phosphatidylcholine, the acyl donor in 
the LCAT reaction, was decreased significantly, whereas all other 
phospholipids were unaffected. The cholesterol-esterifying activity of LCAT 
was significantly lower in cancer patients, whether assayed with endogenous 
substrates (P<0.05), or with an exogenous substrate (P<0.01). However, 
another function of the enzyme, namely the lysolecithin acyltransferase 
activity, was increased (P<0.02), indicating that the enzyme concentration in 
plasma may not be decreased. These results show that the increase in the 
FC/EC ratio in cancer patients is due to an impaired esterification of 
cholesterol by plasma LCAT, probably due to an alteration in the 
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composition of substrate lipoproteins, or the    presence of an inhibitory 
factor (Papasani et al ,, 1996) . Plasma lipids level  reflects dietary lipid 
intake in  individual . There are several reports of elevated Plsma lipid level 
such as total lipid (TL) , phosphalipid (PL) , triglycerides (TG)    total 
cholesterol  (T-C), low density lipoprotein (LDL-C) , and free fatty 
acids(FFA) in pre and post menopausal breast cancer patients . It has been 
postulated that changes in the concentration of serum lipids in the breast 
cancer patients could resulting increase production of  tumor necrosis factor 
and inhibit adipose  lipoprotein lipase activity by the action of insulin . These 
changes impair the catabolism of very low density lipoprotein (VLDL-C) , 
leading to an increase in high density lipoprotein (HDL-C) . Epidemiology 
studies reveal that (HDL-C)and breast cancer are influenced by variables like 
dietary fat intake, alcohol consumption, weight, country of residence 
pregnancy, endogenous hormones , smoking , exercise and socioeconomic 
status . HDL-C level has been shown to be  higher  in subject with 
mammography dysphasia and family history of breast cancer .They have 
however , reported either elevated or decreased level of HDL-C in women 
with breast cancer .Thus HDL-C level alone ,at present , cannot be taken into 
consideration as a causative factor . It was found that patients with more 
advanced breast cancer have significantly lower concentration of HDL-C 
than do patients with less advanced disease . Few studies have  , however , 
directly  addressed the relationship of HDL-C with breast cancer . But a 
relationship of HDL-C  to breast cancer is still a subject of controversy . 
Plasma T-C and LDL-C were found to be significantly elevated whereas 
HDL-C was significantly decreased in breast cancer patients . These studies 
suggests that that higher level of T-C may play important role in 
carcinogenesis (Hassija and Hardeep,2005)                                                        
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1.2 Cytokines    
 
          Cytokines are group of proteins and peptides that are used in 
organisms as signaling compounds .These chemical signals are similar to 
hormones and neurotransmitters and are used to allow one cell to communite 
to another . Cytokines are produced by a wide variety of cell types (both 
haemopoietic, and non-haemopoietic ) , and can effects on both nearby cells 
or throughout the organism . Cytokine is general name , other names include 
lymphokines ( cytokines made by lymphocytes ) monokine ( cytokines 
acting on other leukocytes ) (Wikipedia ,2007) .                                              
1.2.1 Properties of cytokines   
 
       Cytokine are small proteins secreted which mediate and regulate 
immunity , inflammation , and hemopoiesis and must be produced de novo in 
response to immune stimulus .They act by binding to specific  membrane 
receptors , which signal the cell via second messengers , often tyrosine 
kinase , to alter its behavior (gene expression ) . Responses to cytokines 
include increasing or decreasing expression of membrane proteins (including 
cytokines receptors ) , proliferation , and secretion of effector molecules . 
They may act on the cell that secrete them ( autocrine action ) on nearby 
cells( paracrine action )  or on some instanes ( endocrine action ) . It is 
common for different cell types to secrete  the same cytokine or for a singale 
 cytokine to act on several different cell types(pleoittropy ) also they are 
redundant in their activity , meaning similar functions can stimulated by 
different cytokines . Cytokine are often produced in a cascade as one 
cytokine stimulates its target cells to additional cytokines . They can also act 
synergistically (two or more cytokines acting together ) or antagonistically 
(cytokines causing opposing activities ). Their short half life , low plasma 
concentration ,  pleoittropy , and redundancy all complicated the isolation 
and characterization of cytokines (Wikipedia , 2007) .                                      
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1. 2.2 Tumor necrosis factor (TNF)  
 
       Tumor necrosis factor is cytokine involved in systemic 
inflammation and mainly produced by macrophages , but also by 
abroad variety of other cell types including lymphoid cells mast cells , 
indothelial cells , cardiac myocytes , adipose tissues , fibroblasts and 
neuronal tissues . It causes apoptotic cell death cellualar proliferation 
(TNF induces the expression of other autocrine growth factors , 
increases cellular responsiveness to growth factors and induces 
signaling pathways that lead to proliferation) , differentiation , 
inflammation tumorigenesis (TNF induces the expression of the number 
of nuclear  proto-oncogenes aswell as of sereval interleukins) , and viral 
replication . There are two classes of TNF , tumor necrosis factor –
alpha is most well- known member of this class and tumor necrosis 
factor –beta   is a cytokine that induced by interleukin 10 . Although 
researchers are still investigating the exact mechanism by which TNF 
kills cancers cells , it is clear that TNF binds to receptors located on the 
surface of cancer cells , causing a change and then death   of the cell. 
This was found to be true in animal models (Wikipedia ,  2007) . Tumor 
necrosis factor alpha (TNF-alpha) is a potent cytokine with a myriad of 
innate immune anti-tumor properties . TNF-alpha has a critical role in 
the bone and cartilage damage associated with rheumatoid  arthritis . 
TNF-alpha may be involved in the pathogenesis and/or progression of 
gestational diabetes mellitus . TNF-alpha is expressed in myocardium 
during compensated pressure-overload hypertrophy and contributes to 
postischemic myocardial dysfunction.The serum levels of TNF-alpha 
were also significantly elevated in active WG (Wegener's 
granulomatosis) , in the late stages of HIV-associated disease, and in 
the spinal cord of arthritic patients (Taylor, 2001)  . 
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 1.2.3 Cytokines and cholesterol metabolism                                  
       The molecular mechanism by which cytokines affect lipid 
metabolism is not completely known and no data are available on how 
they affect the control of genes expressing the enzymes involved in 
cholesterol and fatty acid biosynthesis . The transcription factors, sterol 
regulatory element binding protein (SREBP)-1 and SREBP-2 are 
particularly important because they promote the activation of genes 
encoding for key enzymes of cholesterol biosynthesis, such as HMG-CoA 
synthetase, HMG-CoA reductase, farnesyl diphosphate synthethase and 
squalene synthethase . SREBP-1 and SREBP-2 are anchored to the 
endoplasmic reticulum membrane and their activity is regulated by sterol 
levels . When cells are deprived of sterols, two-step proteolytic cleavage 
releases a 68-kDa transcriptionally active fragment which migrates into 
the nucleus. When sterols accumulate in cells, this cleavage is prevented, 
so the transcription of target genes declines  (Lusia  et al , 2001) . There 
is evidence for cytokine regulation of cholesterol metabolism in 
herpesvirus-infected arterial cells by the lipoxygenase pathway.They 
possess antiviral activity and have other biological activities such as 
induction of cell proliferation and hemorrhagic necrosis of tumors. Since 
herpes simplex virus (HSV) infection of human vascular cells is known to 
produce a biochemical and cytopathological effect virtually 
indistinguishable from atherosclerosis, we hypothesized that these 
cytokines prevent cholesteryl ester (CE) accumulation in arterial smooth 
muscle cells (SMC) that is seen with herpesvirus  infection   (Etingin , 
and Hajjar  1990) . 
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1. 2.4  Cytokines and breast cancer 
        In recent decades many advances have occurred in the 
understanding of the role of cytokines in breast cancer. New signalling 
pathways of interleukin (IL)-1 family, IL-6, IL-11, IL-18, interferons 
(IFNs) and interferon regulatory factors 1 (IRF-1) and 2 (IRF-2) have 
been found within tumour microenvironments and in metastatic sites. 
Some cytokines (IL-1, IL-6, IL-11, TGFβ) stimulate while others (IL-12, 
IL-18, IFNs) inhibit breast cancer proliferation and/or invasion. So far IL-
2, IFNα, IFNβ and occasionally IFNγ, IL-6, IL-12 have been the 
cytokines used for anti tumour treatment of advanced breast cancer either 
to induce or increase hormone sensitivity and/or to stimulate cellular 
immunity (Nicolini et al , 2006) .  inflammatory cells and cytokines were 
recently suggested to play a key role in breast carcinoma. A large number 
of observations suggest that certain types of inflammatory cells are not 
innocent bystanders at breast tumor sites, and that they actively affect 
tumor development and progression. Inflammatory cells, primarily 
macrophages, may affect these processes via their ability to express a 
large variety of factors, including inflammatory cytokines. These 
cytokines may be secreted not only by inflammatory cells, but also by the 
tumor cells and stroma cells, together establishing a network of factors 
that significantly affects breast cancer (Aben- Baruch , 2002) . 
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Chapter Two 
Materials and methods 
 
1.2 Study area 
             In this study samples were collected from patients who were 
treated at Radiation and Istopes Center Khartoum (RICK), Khartoum 
Teaching Hospital, Khartoum North Teaching Hospital , Omdurman 
Teaching Hospital, and Ombada Teaching Hospital during a period of  
seven months from April to November 2007. 
2.2 Patients selection 
           One hundred females were selected for this study . 50 cases of 
different types of breast cancer patients were chosen randomly for this 
research . They were females between (30) to (70) years old , from 
different parts of Sudan . All of them were suffering from breast cancer 
disease . The fifty cases included two equal groups . One group of (25) 
cases treated by surgery only, while the other group also of (25) cases, 
were treated by surgery and other methods (hormonetherapy, 
chemotherapy, and radiotherapy) . Fifty normal individals apparently 
were used as control . Data presented in appendix (1) was collected from 
each patients at the time of samples collection . 
2.3 Samples collection 
          Blood samples were taken from each patient in plain container, 
then transported immediately to the laboratory, so as to separate serum 
blood . The serum stored in refrigator so as to be analyzed latter for 
cholesterol, lipoproteins cholesterol  fractions and tumor necrosis factor 
(TNF) . 
2.4 Chemical analysis 
          All samples were tested in duplicated unless stated other wise . 
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2.4.1 Cholesterol estimation in serum  
Cholesterol estimated in serum according to the method described by 
(Allain et al,1974 ; Meiattini et al,1978; and Friedman and Young,1997) . 
Principle 
        In the presence of cholesterol esterase, the cholesterol ester in the 
sample are hydrolased to cholesterol and free fatty acids . The cholesterol 
produced is oxidized by cholesterol oxidase  to cholestenone and 
hydrogen peroxide . hydrogen peroxide is detected by chromogenic 
oxygen accepter,phenol-ampyrone,in the presense of peroxidase . The red 
quinine formed, is proportional to the amount of cholesterol present in the 
sample . 
Procedure 
     0.02 ml of blood sample were placed  in clean test tube. There after, 
1ml of the working reagent was added to the tube . In another test tube, 
0.02 ml of standard solution were added together with  1ml of the 
working reagent so as to prepare the standard solution . The blank 
solution was prepared by placing  2ml of the working reagent in clean test 
tube . All tubes were mixed well and incubated for 10 min at 37 C . Then 
the samples and the standard wre read against the blank reagent using 
spectrophotometer at 520 nm . 
Calculations 
Cholesterol (mg/dl) was calculated as follows : 
                  Absorbance of the test          x  concentration of the standard 
               Absorbance of the standard  
 
       Cholesterol  = (mg/dl) 
       Cholesterol  = (mg/dl) x 0.0259 = m mol/l 
 
 
 
 
 18
2.4.2  Estimation of low density lipoproteins cholesterol 
(LDL –C)  
        low of density lipoproteins cholesterol were estimated in serum 
according to the method described by (Assmann et al , 1984 ; Young , 
1995 ; Friedman and Young , 1997) . 
Principle 
low density lipoproteins cholesterol (LDL-C) in the sample precipitate 
with polyvinylsulphate . Their concentration from difference between the 
serum total cholesterol and the cholesterol in the suppermanant after 
centrifugation . The cholesterol is spectrophotometerically measured by 
means of the coupled reactions as described below . 
Cholesterol esters  + H2O    CHE      Cholesterol   +  Fatty acid  
Cholesterol +  ½ O2 + H2O   CHOD   Cholesterol  + ½ H2O2 
2H2O2 +4-Aminoantipyrine + Phenol    POD      Quinoniemine + 4H20 
Reagents 
A . Reagent  1x20ml  polyvinylsulphate  3g/l  polyethyleneglycol  3g/l . 
Cholesterol kit  (biosystem code 18011 and 18044) . 
Procedure 
Precipitation 
1- Into labeled test tubes the following were pipetted : 
 
Sample 0.2 ml 
Reagent A 0.1 ml 
 
2- The tubes were let to stand for 10 minutes at room temperature . 
3- Centrifuted at minimum of 4000 r.p.m for 10 minutes . 
4- The suppermanant was collected carefully . 
 
 19
Colorimetry 
1- Cholesterol reagent was brought to room temperature . 
2- Into labeled test tubes the following were pipetted : 
 
 Blank Standard(ST) Sample (S) 
Distilled water 20µl - - 
Cholesterol standard - 20µl - 
Sample suppermanant - - 20µl 
Cholesterol reagent 1.0 ml 1.0 ml 1.0 ml 
 
3- The tubes were incubated for 10 minutes at room temperature . 
4- The absorbance(A) of the sample and the standard was measured at 
520 nm against the blank . 
Calculations 
LDL-Cholesterol (mg dl)   =  Absorbance (A)    X  360  
                                            Absorbance (st)     
2.4.3 Estimation of high density lipoproteins cholesterol 
(HDL –C)  
        High density lipoproteins cholesterol were estimated in serum 
according to the method described by ( Grove , 1979 ; Burstein et al, 
1980 ; Young , 1995 ; Friedman and Young ,1997 )  . 
Principle 
          Very low density lipoproteins and low density lipoproteins  (LDL) 
in the sample were precipitated with phosphotungstate and magnesium . 
The suppermanant contain high density lipoproteins (HDL-C) . The 
HDL-C cholesterol is then spectrophotometerically measured by means 
of the coupled reactions as described below . 
Cholesterol esters  +  H2O    CHE     Cholesterol  + Fatty acid  
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Cholesterol + ½ O2 + H2O   CHOD   Cholesterol + ½H2O2 
2H2O2 +4-Aminoantipyrine + Phenol    POD      Quinoniemine + 4H20 
Reagents 
A.Reagent 1x50 phosphotungstate 0.4 mmol magnesium chloride 20 
mmol . 
S.HDL Cholesterol standard 1x5ml cholesterol 15mg/dl . Aqueous 
primary standard . 
Cholesterol kit (biosystem code 18011 and 18044) . 
Procedure 
Precipitation 
5- Into labeled test tubes the following were pipetted : 
Sample 0.2ml 
Reagent A 0.5ml 
6- The tubes were let to stand for 10 minutes at room temperature . 
7- Centrifuted at minimum of 4000 r.p.m for 10 minutes . 
8- The suppermanant was collected carefully . 
Colorimetry 
5- The Cholesterol reagent was brought to room temperature . 
6- Into labeled test tubes the following were pipetted : 
 Blank Standard(ST) Sample (S) 
Distilled water 100µl - - 
Cholesterol standard - 100µl - 
Sample suppermanant - - 20µl 
Cholesterol reagent 1.0 ml 1.0 ml 1.0 ml 
 
7- The tubes were incubated for 10 minutes at room temperature . 
8- The absorbance(A) of the sanple and the standard was  measured at 
520 nm against the blank . 
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Calculations 
HDL-Cholesterol (mg dl)  =   Absorbance (A)   X  52.5  
                                            Absorbance (st)     
2.4.4  Tumor Necrosis Factor alpha (TNF-alpha)   
          This was assayed by the assay max human Tumor Necrosis Factor .  
Method described by (Taylor , 2001 ; Coughlan , 2001) . 
Principle of the Assay  
 
       The Assay Max mouse TNF-alpha ELISA kit is designed for 
detection of TNF-alpha in mouse serum or cell culture supernatants . This 
assay employs a quantitative sandwich enzyme immunoassay technique 
that measures TNF-alpha in 3.5 hours . A murine monoclonal antibody 
specific for mouse TNF-alpha has been pre-coated onto a microplate . 
TNF-alpha in standards and samples is sandwiched by the immobilized 
antibody and a biotinylated polyclonal antibody specific for mouse TNF-
alpha, which is recognized by a streptavidin-peroxidase conjugate . All 
unbound material is then washed away and a peroxidase enzyme substrate 
is added . The color development is stopped and the intensity of the color 
is measured . 
Reagents 
 
1-TNF-alpha Microplate: A 96-well polystyrene microplate (12 strips of 
8 wells) coated with a murine monoclonal antibody against TNF-alpha . 
2- Sealing Tapes: Each kit contains 3 pre-cut, pressure-sensitive sealing 
tapes that can be cut to fit the format of the individual assay . 
3-TNF-alpha Standard: Recombinant mouse TNF-alpha in a buffered 
protein base (4 ng, lyophilized) . 
4- Biotinylated TNF-alpha Antibody (100x): A 100-fold biotinylated 
polyclonal antibody against TNF-alpha (80 µl) . 
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5-Streptavidin-Peroxidase Conjugate (SP Conjugate): A 100-fold 
concentrate (90 µl) . 
6- Mix diluent Concentrate (10x):A 10-fold buffered protein base(20ml) . 
7- Wash Buffer Concentrate (10x): A 10-fold concentrated buffered 
surfactant (2 x 30 ml) . 
8-Chromogen substrate: A ready-to-use stabilized peroxidase chromogen 
substrate tetramethylbenzidine (8 ml) . 
9-Stop solution: A 0.5 N hydroxychloric acid (12 ml) to stop the 
chromogen substrate reaction . 
Reagent Preparation 
 
            All reagents must take to room temperature before use . 
Standard Curve :  The  2ng  of   human   TNF-alpha  Standard  was 
reconstituted with2ml of mix diluent to generate a 1 ng/ml of solution. 
The standard  was allowed to sit for 10 minutes with gentle agitation prior 
to making dilutions.Triplicate  standard  points were  prepared  by serially 
diluting the TNF-alpha standard solution twofold with equal volume of 
mix diluent to produce  0.5, 0.25, 0.125, and 0.0625 ng/ml. Mix diluent 
served as the zero standard (0 ng/ml) .   
   
standard point Dilution TNF-alpha ng/ml 
P1 Standard (1 ng/ml) 1.0000 
P2 1 part p1 + 1 part mix dilution 0.5000 
P3 1 part P2+ 1 part mix dilution 0.2500 
P4 1 part P3+ 1 part mix dilution 0.1250 
P5 1 part P4+ 1 part mix dilution 0.0625 
P6 1 part P5+ 1 part mix dilution 0.0313 
P7 1 part P6+ 1 part mix dilution 0.0156 
P8  Mix dilution 0.0000 
 
Mix diluent Concentrate (10x): The mix diluent  Concentrate was diluted 
1:10 with reagent grade water . 
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Biotinylated TNF-alpha Antibody (100x): Spin down The antibody was 
spined briefly and diluted the desired amount of the antibody 1:100 with 
mix diluent . 
Wash buffer Concentrate (10x): The wash buffer Concentrate  was 
diluted 1:10 with reagent grade water . 
SP Conjugate (100x): The SP Conjugate was spined down briefly and the 
desired amount of the conjugate was diluted1:100 with mix diluent .   
Assay Procedure 
            All  reagents working standards and samples  were prepared as 
instructed.Excess microplate strips were removed from the plate frame 
and  returned  immediately  to the foil pouch  with inside desiccanted . 
The pouch resealed securely to minimize exposure to water vapor and 
stored in a vacuum desiccator . 
50 µl  of   Standard or  sample were  added  per  well. Wells covered  and 
incubated for two hours .  
The timer was stared after the last sample addition . Wash was  performed 
five times with 200 µl of wash buffer. The  plates were inverted  and the 
contents,were decanted , and were hit  4-5 times on absorbent paper towel 
to complete  liquid removed at each step . 
50 µl of biotinylated TNF-alpha antibody was added to each well and 
incubated for 60 minutes . 
Wash  was performed five times with 200 µl of wash buffer as above . 
50 µl of   streptavidin-peroxidase conjugate  was  added   per  well  and 
incubated for 30 minutes . 
Wash  was performed five times with 200 µl of wash buffer as above . 
50 µl of chromogen substrate were added per well  and   incubated for 
approximately 10 minutes or till the optimal blue color density  
developed . 
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50 µl  of  stop solution was  added to  each well . The  color was  changed 
from blue to yellow.The absorbance was read immediatly on a microplate   
reader  at a wavelength of 450 nm  . 
Data Analysis  
     The mean value of the duplicate readings were  calculated for each 
standard and sample. To generate a Standard Curve, a graph was ploted 
using the standard concentrations on the x-axis and the corresponding 
mean 450 nm absorbance on the y-axis . The best-fit line can be 
determined by regression analysis of the linear portion of the curve . The 
unknown sample concentration was determined from the Standard Curve 
and the value were multiplied  by the dilution factor . 
2.5 Statistical analysis 
The data was statistically analyzed by using statistical package for social 
science (SPSS) (2007) . 
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Chapter Three 
Results 
The effects of breast cancer on serum total cholesterol, lipoproptein 
cholesterol , and tumor necrosis factor in female patients are presented in 
table (1) . 
3.1 The effects of breast cancer on serum  cholesterol . 
        The two groups of breast cancer patients, showed  significantly lower 
cholesterol value, compared to the non cancer individuals, but difference in 
the group that  were treated  by surgery only and did not receive any other 
treatment yet showed highly  significant (P>0,01) lower cholesterol value , 
compared to the control , Whereas , group B which started to receive other  
anticancer treatment showed significantly (P>0,05) lower cholesterol value , 
compared to the control figure (3) .  
3.2  The effects of breast cancer on serum  LDL-C . 
          LDL-C value was also very low in  patients group A and B compared 
to the control . The difference in group A was highly significant (P>0,01) 
and in group B was signigficant (P>0,05) and the different between two 
groups was also signigficant (P>0,05)  figure (4) .   
3.3 The effects of the cancer on serum HDL-C . 
         The levels of the HDL-C value were within the same levels in the two 
patients groups and the control . Only group B showed slight lower non- 
significant value figure (5) .   
3.4 The effects of the cancer on serum TNF-alpha . 
        The level of TNF-alpha was highly  significant (P>0,01) in group A 
and group B compared to the control  . Group A showed lower value 
compared to group B , figure (6) .   
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Table (1) : The effect of disease condition on serum total cholesterol, 
lipoproteins cholesterol , and TNF-alpha in breast cancer patients . (Mean ± 
SE) 
 
Patients category  Cholesterol 
(mg/dl) 
LDL-C 
(mg/dl) 
HDL-C 
 (mg/dl) 
TNF- alpha 
ng/ ml 
Normal range  130 - 250  50 -140  35 - 75 3 - 13 
Control (N=25) 189.6 ± 7.8 a 
 
81± 2.8 a 
 
41.88± 1.9 a 
 
12.14± 0.6 a 
 
Group A (N=25) 
**129.1 ±7.7 b **32.2 ±2.8 c 37.04±1.9 a 
  
**14,16±0.4 b
Group B (N=25) *161.52 ±7.7 c  *43,96±2.8 b 42,64±1.9 a 
 
**16,16±0.4 c
 
Mean values in same column with different superscripts letters are 
significantly different. 
  
*     = (P< 0.05) significant compared to the control 
* *  = (P< 0.01) highly significant compared to the control 
 
Group A = patients were treated by surgery only 
Group B = patients were treated by surgery and others methods of treatment 
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Figure  (4) : The level Serum LDL-C in different groups 
of patients.
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Figure (3) : The level serum total cholesterol in 
different groups of patients .
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Figure  (5) :The level Serum HDL-C in different groups of patients.
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Figure  (6):The level Serum TNF - alpha in different groups of patients.
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3.5 The influence of parity, cancer stages, and age on serum total 
cholesterol, and lipopropteins cholesterol  in group A  
3.5.1 Serum total cholesterol , and lipopropteins cholesterol values 
during diffirent stages of breast cancer . 
Value of serum total cholesterol shown in figure (7) were low in stage 3 and 
stage 4 of breast cancer and were highly significant (P>0,01) compared to 
the control . However, the level cholesterol in of stage 3 compared to stage 4 
was not  significantly different table (2) . LDL-C value was highly 
significant in stage 3and stage 4 compared to the control . Where was no 
different in LDL-C level  in stage 3 compared to stage 4  as seen in figure 
(8) . HDL-C values of stage 3 showed no significant  difference when 
compared to the control as  shown in figure (9) . 
3.5.2 Serum total cholesterol, and lipopropteins values related to parity 
of breast cancer patients. 
In all parity total cholesterol was found to be low in cancer patients and the 
difference was highly significant (P>0,01) as shown in figure (10). HDL-C 
was not affected compared to the control as illustrated in figure (12), 
whereas, the value of LDL-C was low and the difference was highly 
significant compared to the control as shown in figure (11). The group of 
zero parity showed the lowest LDL-C and highest HDL-C  levels compared 
to other group table  (4). 
 3.5.3 Serum total cholesterol , and lipopropteins cholesterol values 
related to age in breast cancer patients . 
In all the age groups total cholesterol level was low and the difference was 
highly significant (P>0,01) as shown in figure (13) whereas, levels  for 
HDL-C were non-significantly different compared to the control as 
illustrated in figure (15). The value of LDL-C were highly significant 
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(P>0,01) lower compared to the control as shown in figure (14)  . The lowest 
level was reported in the  age group between 51 to 60 years old table (6) . 
3.6 Alterations serum total cholesterol, and lipopropteins cholesterol  in 
patients group B. 
 3.6.1 Serum total cholesterol, and lipopropteins cholesterol  values 
during diffirent stages of breast cancer . 
Value of serum total cholesterol and HDL-C in figure (7) and figure (9) 
respectively showed non-significant difference in all the stages of breast 
cancer compared to the control and within the stages . Whereas, LDL-C 
value showed a highly significant difference in all  stages compared to the 
control. the lowest level was  showed  in patients of stage 3 table (3) . 
3.6.2 Serum total cholesterol,and lipopropteins cholesterol  values 
related to parity  in breast cancer patients . 
Value of serum total cholesterol and HDL-C showed in figure (10) , and 
figure (12)  in all parity of breast cancer patients compared to the control and 
within the groups, showed non-significant difference . Whereas, LDL-C 
values  showed  a highly significant (P>0,01) difference   in all  parity 
groups compared to the control table (5) . 
3.6.3 Serum total cholesterol, and lipopropteins cholesterol values 
related to age in breast cancer patients . 
Value of serum total cholesterol  and HDL-C showed in figure (13) and 
figure (15) in all age groups of breast cancer patients compared to the 
control and within the groups showed non-significant difference . However, 
LDL-C value showed a highly significant difference in all age groups 
compared to the control table (7) . 
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Table (2) : Serum total cholesterol,and lipopropteins cholesterol values 
during diffirent stages in  group A . (Mean ± SE) 
 
Parameters Normal range Control  Stage -3 Stage - 4 
T-C(mg/dl) 130 -250 189.6±5.9a ** 135.4±8.3b **122.3±8.3b 
LDL-C(mg/dl) 50 -140 81±3.3a ** 35.7± 3.8 b ** 28.5± 4 b 
HDL-C(mg/dl) 35 -  75 41.9± 1.6a 39.6±2.3a 34.4±2.3a 
 
Mean values in same rows with different superscripts letters are significantly 
different. 
  
*     = (P< 0.05) significant compared to the control  
* *  = (P< 0.01) highly significant compared to the control  
Table (3) : Serum total cholesterol,and lipopropteins cholesterol values 
during diffirent stages in group B. (Mean ± SE) 
 
Parameters Control Stage-2 Stage -3 Stage - 4 
T-C(mg/dl) 189.6±8,4a 144.5±  21 a 168.6± 14 a 161.6± 12.1 a 
LDL-C(mg/dl) 81±3.2a ** 46 ± 8 b ** 40.6± 5.3 b ** 45.6± 4.6 b
HDL-C(mg/dl) 41.9±2.2a 45 ± 5.4a 42.9± 3.6a 41.7 ±3.1a 
 
 
Mean values in same rows with different superscripts letters are significantly 
different. 
 *     = (P< 0.05) significant compared to the control  
* *  = (P< 0.01) highly significant compared to the control  
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Table (4) : Serum total cholesterol,and lipopropteins cholesterol values 
related to parity  in  group A. (Mean ± SE). 
Parameters  Control Parity- 0 Parity -1 Parity- 2-8 
T-C (mg/dl) 189.61± 6.1a **136.5±15.2 b **138± 21.5 b **126.4± 6.9 b 
LDL-C(mg/dl) 81± 2.8 a **28.5± 6.9 b **39.5± 9.8 b **33.53± 3.1b 
HDL-C(mg/dl) 41.9± 1.7a 41± 4.1 a 31.5± 5.9 a 36.8± 1.9 a 
Mean values in same rows with different superscripts letters are significantly 
different. 
 
 *     = (P< 0.05) significant compared to the control  
* *  = (P< 0.01) highly significant compared to the control 
Parity = Number of children . 
 
 
Table (5) : Serum total cholesterol,and lipopropteins cholesterol values  
related to parity in group B . (Mean ± SE) 
Parameters  Control Parity- 0 Parity -1 Parity- 2-8 
T-C (mg/dl) 189.6±8,25a 155.5± 20.6 a 160 ± 29.19 a 154.6± 9.5 a 
LDL-C(mg/dl) 81±3.3a ** 40.25± 6.2b ** 44.5± 11.5 b **44.3±3.7 b 
HDL-C(mg/dl) 41.9±2.1a 40.5± 5.1 a 50.5± 7.3 a 43± 2.4 a 
Mean values in same rows with different superscripts letters are significantly 
different . 
 
 *     = (P< 0.05) significant compared to the control  
* *  = (P< 0.01) highly significant compared to the control 
Parity = Number of children . 
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Table (6) : Serum total cholesterol,and lipopropteins values related to age   
in  group A . (Mean ± SE) . 
 
Parameter 
(mg/dl) 
Control 30-40 
Years 
41-50 
Years 
51-60 
Years 
61-70 
Years 
T-C 189.6±8,2a **129.5±10.3 b **135.9±10 b **119±7.4 b **130.5±21.5b 
LDL-C 81±3.3a ** 34.1± 4.8b ** 32.3± 5.1 b *28.7± 5.9b ** 32 ± 10.1 b 
HDL-C 41.9±2.1a 37.1± 5.7 a 41± 2.8 a 32 ± 1.3 a 43 ± 5.6 a 
Mean values in same rows with different superscripts letters are significantly 
different. 
  
*     = (P< 0.05) significant compared to the control.  
* *  = (P< 0.01) highly significant compared to the control  
 
Table (7) : Serum total cholesterol,and lipopropteins values related to age  
in  group B . (Mean ± SE). 
Parameter 
(mg/dl) 
Control 30-40 
Years 
41-50 
Years 
51-60 
Years 
61-70 
Years 
T-C 189.6±8,2a 134.1±  15.1 a 161.7±  11a 140± 28.2 a 186.7 ± 22 a 
LDL-C 81±3.3a ** 43± 6.2b ** 46.1± 4.5 b **32± 11.5b **42.3 ± 9.4 b
HDL-C 41.9±2.1a 44.9± 3.8 a 45.8± 2.8 a 33.5 ± 7.1 a 37± 5.6 a 
 
Mean values in same rows with different superscripts letters are significantly 
different. 
 *     = (P< 0.05) significant compared to the control.  
* *  = (P< 0.01) highly significant compared to the control. 
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Figure (7) : The level of cholesterol in patients group A and group B 
during different stages of breast cancer.
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Figure  (8) : The level LDL-C in patients group A and group B      
         during different stages of breast cancer.
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Figure  (9) : The level HDL-C in patients group A and groupB      
   during different stages of breast cancer.
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Figure  (10) : The level serum cholesterol  in patients group A 
and group B related to parity.
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Figure  (11) :The level LDL-C in patients group A and 
group B related to parity.
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Figure  (12) : The level serum HDL-C in patients group A and  
group B related to parity.
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Figure (13) : The level serum cholesterol in patients 
group A and group B related to age group.
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Figure (14) : The level serum LDL-C in patients group A group 
B related to age group.
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Figure (15) : The level HDL-C in patients group A  and group B 
related to age group.  
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Chapter Four 
Discussion 
 
            Human mammary tissue metabolizes lipids from plasma affected by 
female gonadal hormones. Malignant proliferation of breast tissue in women 
has been associated with changes in plasma lipid and lipoproteins levels 
(Lane, 1995).The question arises whether hypolipidemia is predisposing 
factor or result of cancer ? However, earlies studies (Eichholzer et al, 2000 ; 
Feinlieb , 1983 ; Peto et al , 1981  )  have reported that hypolipidemia may 
result due to the direct lipid lowering effect of tumor cells or some 
secondary malfunction of the lipid metabolism or secondary to antioxidant 
vitamins . Several prospective  and retrospective studies ( Schatzkin ,1988 ;   
Halton 1998 ; and Budd ,1986 )  have shown an inverse association  between 
blood lipid profile and different cancers (Patel et al, 2004) . In   the present 
work , serum total cholesterol and its fractions  , were estimated together 
with tumor necrosis  factor -alpha in cases of breast cancer  . The patients 
were  divided into two groups one of them just operated on to remove the 
tumor and the changes in metabolism due to malignancy  are still exisiting . 
The other group of patients was started  to receive other types of treatment 
and the influence of cancer was statred to be deceased , All these values 
were compared to non cancer patients as control . 
4.1 The effects of breast cancer on serum total cholesterol ,  lipoproptein 
cholesterol , and tumor necrosis factor in female patients. 
4.1.1   Serum total cholesterol . 
            In this work,the serum total cholesterol showed lower levels in all 
disease condition compared to the control . The difference was significant 
(P<0.05) in group B who were started to receive other types of treatment 
 40
after surgery and highly significant (P<0.01) in group A where patients were 
just treated by  surgery . This agrees with the result of Anderson , (2005) 
who focused on regions of the membrane where cholesterol is enriched. 
These regions, called "lipid domains,"  they are more rigid than the rest of 
the cell membrane because of cholesterol , and play a critical role in 
organizing signaling machinery at the cell surface. The correct arrangement 
of signaling modules in these domains is vital for communication inside the 
cell and is dependent on proper levels of cholesterol. Cholesterol can work 
outside the membrane to regulate a key signaling pathway that occurs inside 
the cell. Through an interaction with a protein called the "oxysterol binding 
protein" (OSBP), cholesterol holds together a group of enzymes that 
deactivates extracellular signal-related kinase (ERK). Overactive ERK is 
associated with multiple cancers. When the amount of cholesterol in lipid 
domains is normal, the OSBP-cholesterol complex keeps the amount of 
active ERK under control. When cholesterol in the domains gets too low, 
however, the complex falls apart, leading to abnormally high levels of active 
ERK. Dr. Anderson and colleagues noticed that OSBP has binding sites for 
both cholesterol and the other proteins in the complex. They believe that 
when cholesterol binds OSBP it changes shape to bind the key enzymes in a 
way that allows them to work together to control deactivation of ERK. When 
lipid domain cholesterol gets low, OSBP loses its cholesterol and no longer 
is able to bind the enzymes that deactivate ERK, keeping it active . So the 
low cholesterol levels reported in the present work could be explained to be  
the cause of low lipid domains then consequestly its less binding to the 
OSBP and the ERK not activated by the complex then its over activity result  
in cancer in these patients, who still showed significantly lower levels of 
cholesterol in their blood even after surgery and other treatments of cancer . 
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The higher levels of cholesterol and LDL-C in group B , which received 
other treatments after surgery  compared to group (A) which only treated  by 
surgery could be due to decrease utilization of cholesterol by neoplastic cells 
as , reported by Patel et al. (2004), who observed significant decrease in 
plasma total cholesterol in cancer patients compared to the controls. They  
suggested that the lower levels of plasma cholesterol and other lipid 
constituents in patients might be due to their increased utilization by 
neoplastic cells for new membrane biogenesis. The increased utilization of 
cholesterol due to just rapid growth was also reported by Yip et al, (2006) 
who found that total cholesterol, LDL-C and Apo B were lowest in the first 
12 month after birth in children compared to other age groups. However, 
Tornberg et al, (1989) reported  that cancer incidence and mortality from 
cancer in relation to serum cholesterol levels in 710 individuals, total cancer 
incidence and total cancer mortality were negatively correlated to serum 
cholesterol level (P<0.001) . The negative correlations were most 
pronounced during the first years of follow-up . Cancer mortality data 
showed a stronger negative association to cholesterol than did incidence data 
during the first 10 years of follow-up (P<0.05) . Efforts by investigators and 
clinicians to lower serum cholesterol to prevent cardiovascular disease are, 
according to their findings, not likely to increase cancer mortality risks but 
would extend life, irrespective of cause of death. Furthermore, Potischman et 
al, (1991) found that plasma cholesterol values were lower in breast cancer 
cases presented with more advanced stages of cancer, suggesting that 
metabolic effects of clinical and preclinical breast cancer may lower 
cholesterol levels . On the other hand this disagrees with Ray and Husian 
(2000) who found that plasma total cholesterol was significantly elevated 
(P<0.05), among breast cancer patients as compared to the controls. Their 
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study suggested that higher levels of TC and TG may play important role in 
carcinogenesis. Findings in patients of group B who received other types of 
treatment after surgery agrees with the result of Rossner and Wallgren 
(1984) who found that, serum total cholesterol level were lower in breast 
cancer patients who received tomaxifen (hormone therapy) compared to 
healthy individuals due to oestrogen-like effect on lipoprotein and protein 
metabolism. Also agrees with Alexopoulos et al, (1992) who found that, 
breast cancer patients as an exception that having lower level of total 
cholesterol and LDL-C while other cancer patients were found to have 
significantly increased level both of these parameters. Although there 
findings were based on a rather small number of patients, they indicated that 
the lipid and lipoprotein disorder reported in cancer patients are reversible 
by effective treatment of the tumor, suggesting that these disorders are a 
secondary phenomenon of malignancy. Furthermore, Camerini et al, (2007) 
found significant decrease in total cholesterol during hormonetherapy 
(Fulvestrant) in patients of breast cancer due to the lowering effect of 
fulvestrant in hormone-sensitive metastatic breast cancer patients . On the 
other hand this disagrees with the findings reported by Jolanta, (1999), who 
found that, the increase of total cholesterol was not significant in patients of 
malignant breast cancer after chemotherapy .  
4.1.2 Serum LDL-C 
  The levels of LDL-C in both cancer groups in this study were 
significantly lower (P<0.01) than in the control . In group A this finding 
agrees with Knapp et al, (1991) who found that, LDL-cholesterol 
concentrations in breast cancer patients with boney metastases were 
significantly lower (P<0.05) compared to the control. On the other hand this 
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disagrees with Ray and Husian, (2000) who reported that, plasma TC 
(P<0.05), and LDL-C and TG (P<0.05) were found to be significantly 
elevated among breast cancer patients as compared to the controls . 
Whereas, plasma HDL-C concentration and vitamin C and E (P<0.01) were 
observed to be significantly decreased in breast cancer patients than in the 
controls. They suggested that,the elevated plasma LDL-C concentration, 
which is more susceptible to oxidation, may result in higher lipid per 
oxidation in breast cancer patients. Furthermore, decreased concentrations of 
LDL-C and vitamin C and E are not likely to be sufficient enough to counter 
higher reactive oxygen metabolites (ROMs) production reported earlier in 
breast cancer patients that may cause oxidfative stress leading to cellular and 
molecular damage thereby resulting in cell proliferation and malignant 
conversions . Findings in patients of group B in this work agress with 
Jolanta, (1999), who found that after chemotherapy the level LDL-C 
significantly decreased in malignant breast cancer patients (before and after 
menopause). Also agrees with studies carried by Alexopoulos et al, (1992) 
who found that, breast cancer patients having lower levels of LDL 
cholesterol values during chemotherapy. But it disagrees with the result of 
Rossner and Wallgren (1984) who found that concentration of serum LDL-C 
increased (P<0.05) in breast cancer patients after surgical treatment only . 
4.1.3 Serum HDL-C 
 The level of HDL-C was found to be non significantly changes in all 
disease conditions compared to the control in this study. These findings 
agree with Tanya et al, (2004) who reported no statistically significant 
differences in the high-density-lipoprotein-containing cholesterol between 
patients and controls . Also agree with Hassija and Hardeep,  (2005) who 
found that HDL-C values were not significantly difference in the patients 
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compared to the control. But relationship of HDL-C to breast cancer is still 
controversy. Thus HDL-C level alone cannot be taken into consideration as 
a causative factor. This finding disagrees with Ferraroni (1993), whose 
studies were evaluated HDL-cholesterol (HDL-C) as a marker of 
breastcancer risk . It is based on several epidemiological and biological 
studies and is justified by the rising incidence of breast cancer throughout 
the world . Their results indicated that high HDL-C levels should be 
especially checked in women aged >60 years, or in premenopausal women, 
or in postmenopausal women with an early menopause . However Camerini 
et al, (2007) found that, HDL-C value did not show any significant changes 
during hormonetherapy. Also Alexopoulos et al, (1992) reported that, free 
cholesterol and serum HDL-C did not show any significant changes I 
patients of breast carcinoma during chemotherapy. Whereas, this disagree 
with the finding of Morimoto and Kho, (2004) who found that, significant 
increase HDL-C in surgically-treated patients with breast cancer after 
received hormoetherapy and chemotherapy .   
4.1.4 Serum tumor necrosis factor 
          In this study, the serum tumor necrosis factor increased 
significantly (P<0.01) in all patients compared to control. This result agrees 
with the study  of Nenova and Kovatchey , (2000) who found that serum 
TNF- α was elevated in patients with breast cancer and other cancer. They 
are considered that elevated serum TNF-α levels on  one hand could have a 
prognostic value for breast carcinoma patients, and on the other hand they 
could serve as evaluation criteria for the effectiveness of cytostatic therapy. 
Elevation of serum TNF-α activity can have a prognostic significance for 
advanced cancer patients in relation both to the faster progress of the tumour 
process and their survival, and to the therapeutic effect of cytostatic 
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treatment on the disease . It is also agrees with Wei-Jen Chen et al, (1997) 
who found that serum tumor necrosis factor-alpha concentration has been 
found to be increased in the circulation of patients with malignancy . Their 
study was designed with the aim to investigate any correlation between the 
serum tumor necrosis factor alpha concentrations may be valuable parameter 
for reflecting the severity of staging for invasive breast cancer. Furthermore, 
Jablon et al, (2001) found that, serum levels of TNF-α and IL-6 in breast 
cancer patients were significantly higher than in the control (P<0.05) . On 
the other hand this disagree with Rozlya  et al, (2003) found no association 
between breast cancer risk and serum levels of TNF-α or its soluble 
receptors . The potential for a protective role for TNF-α or its soluble 
receptors . The potential for a protective role for TNF-α in breast cancer may 
be more complicated than for such a hypothesized role in non-dependent 
types of cancer because TNF-α coordinately stimulates the activities of the 
enzymes involved in estrogen synthesis in both normal and malignant breast 
tissue. Also, the role of TNF-α in cancer, in general, is paradoxical with 
some evidence suggesting that its local production enhances, through 
inflammatory mechanisms , tumor development and spread . Thus , 
exoogenous TNF-α  antagonist , including that are used to treat chronic 
inflammatory  disease , might reduce risk . Also it is disagrees with the 
finding of Tsavaris  et al,  (2002) who found that, serum levels of TNF-
α and IL-1 was decrease  in patients with advance breast cancer undergoing 
chemotherapy  with taxanes .                                                    
4.2 The levels serum cholesterol and lipoproteins cholesterol in patients 
of group A and group B as effected by  cancer stages, parity, and age . 
4.2.1 The effect of  cancer stages on the levels serum cholesterol and 
lipoproteins cholesterol . 
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              In the present study the decreased  level of serum cholesterol and 
LDL-C has been observed in all different stages of breast cancer patients,but 
not related with advancing stages. However, in group B the values of total 
cholesterol was not much different from control in different stages and was 
non significant. Furthemore in all patients HDL-C value was found to be 
non-significant in different stages.Cholesterol was not affected by  cancer 
stage  in the  present study . 
4.2.2 The effect of  parity on the levels serum cholesterol and 
lipoproteins cholesterol .   
              This study indicate that serum cholesterol and LDL-C levels were  
significantly lower  in all parity cases,but in patients of group B total 
cholesterol was non-significant . But in all patients HDL-C value was found 
to be non-significantly  difference. The number of paraties did not affect the 
level of cholesterol in patients of this work . 
4.2.3 The effected of   age on the levels serum cholesterol and 
lipoproteins cholesterol . 
      In present study serum total cholesterol and LDL-C levels were highly                          
significant in the different age group,but in patients group B total cholesterol 
was non-significant.However,in all patients HDL-C value was found to be 
non-significant. 
               Since  no data was avaible about the correlation between lipid 
profile , and treatable breast cancer patients  related to parity , cancer stages, 
and age group , so it is suitable to compare this findings with that was done 
without referring to any clinical parameter.  
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Conclusions 
 
             Findings, in this study agree with the majority of the previous 
studies in that,breast cancer patients has significantly low level of total 
cholesterol and low density lipoprotein cholesterol whereas, high density 
lipoprotein cholesterol was found to be non-significantly affected . The 
higher  levels found in the group of patients which started to receive other 
types of treatment , compared  to the group received only surgery , may 
indicated either , they started to improve  and restore normal cholesterol 
metabolism or they may could have very low cholesterol  levels from the 
start and just maintained their normal levels . 
         The persisting significant association with low cholesterol , especially 
in breast cancer, need further investigation of cancer  with a long follow-up 
in order to answer the question that whether the decline in serum cholesterol 
in cancer patients is  the cause of malignancy or it is simply result of it .  
        So, it is recommened large number of patients should be investigated to 
confirm this results or not and cancer stages, types, age group,and parity 
undertaken in consideration in the study .  
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Appendix(1) : Data was collected from each patients at the time of 
sample collection. 
Appendix(1-A) : The control and patients in perecentage according to 
age group. 
 
 30-40years 41-50years 51-60years 61-70years 
Patients 32% 42% 16% 10% 
Control 46% 41% 12% 1% 
Appendix(1-B) :The control and patients in perecentage according to 
parity. 
 
 Parity No-0 Parity No-1 Parity No-2-8 
Patients 18% 8% 74% 
Control 13% 5% 82% 
 
Appendix(1-C) : The control and patients in perecentage according to 
stages of cancer. 
 
 Stage-2 Stage-3 Stage-4 
Patients 8% 44% 48% 
Appendix(1-D) : The incidence of the breast cancer of female with     
                           geographical location in the Sudan. 
Appendix(1-E) : The incidence of the breast cancer in  females  with the     
                           type of tribe in the Sudan in the present study . 
 
Tribe Perecentage 
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Gallia 20% 
Gawama 20% 
Zagawa 10% 
Danagla 10% 
Shiagia 8% 
Mahas  6% 
Bedeeria 4% 
Hamer 4% 
Gamah 4% 
Denka 2% 
Niweer 2% 
Falata 2% 
Hasania 2% 
Nupa 2% 
Magarba 2% 
Bagara 2% 
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ABSTRACT  
BACKGROUND: The changes in lipid profile have long been associated with cancer because 
lipids play a key role in maintenance of cell integrity. AIMS: The present study evaluated 
alterations in plasma lipid profile in untreated head and neck cancer patients as well as 
patients with oral precancerous conditions (OPC) and its association with habit of tobacco 
consumption. MATERIAL AND METHODS:This hospital-based case control study included 
184 head and neck cancer patients, 153 patients with OPC and 52 controls. Plasma lipids 
including: (i) Total cholesterol, (ii) LDL cholesterol (LDLC), (iii) HDL cholesterol (HDLC) (iv) 
VLDL cholesterol (VLDLC) and (v) triglycerides were analysed by spectrophotometric kits. 
STATISTICAL ANALYSIS USED: Student's t-test was performed to compare mean values of 
the parameters. RESULTS: A significant decrease in plasma total cholesterol and HDLC was 
observed in cancer patients (p=0.008 and p=0.000 respectively) as well as in patients with 
OPC (P=0.014 and P=0.000, respectively) as compared to the controls. The plasma VLDL 
and triglycerides levels were significantly lower in cancer patients as compared to the patients 
with OPC (P=0.04) and controls (P=0.059). The tobacco habituates showed lower plasma 
lipid levels than the non-habituates. Our data strengthen the evidence of an inverse 
relationship between plasma lipid levels and head and neck malignancies as well as OPC. 
CONCLUSION:The lower levels of plasma cholesterol and other lipid constituents in patients 
might be due to their increased utilization by neoplastic cells for new membrane biogenesis. 
The findings strongly warrant an in-depth study of alterations in plasma lipid profile in head 
neck cancer patients.  
Key Words: Lipids, Cholesterol, Triglycerides, Head and neck cancer, Oral precancerous 
conditions.  
INTRODUCTION  
Lipids are major cell membrane components essential for various biological functions 
including cell growth and division of normal and malignant tissues. Usefulness of variations in 
tissue/blood cholesterol levels in diagnosis and treatment of various diseases has been 
studied by several workers. Although, its prime role in pathogenesis of coronary heart disease 
has been consistently found, researchers have reported association of plasma/serum lipids 
and lipoproteins with different cancers.1-4 The alterations in the circulatory cholesterol levels 
have been found to be associated with etiology of breast cancer and colorectal cancer.5-7 
However, only a few reports are available on plasma lipid profile in head and neck cancer.1,8 
Head and neck cancer is one of the leading causes of morbidity and mortality due to cancer. 
Its incidence is much higher in Asian countries, as compared to the West. At our Institute 
(The Gujarat Cancer and Research Institute), head and neck cancer accounts for about 
2300 new cases every year which is around 25.3% of all cancer cases.9  
The habit of tobacco consumption is a known etiologic factor for development of oral 
precancerous diseases and head and neck cancer.10,11 Patients with oral precancerous 
conditions (OPC) have also been reported to show a significant tendency to develop cancer.12 
It is believed that tobacco carcinogens induce generation of free radicals and reactive oxygen 
species, which are responsible for high rate of oxidation/peroxidation of polyunsaturated fatty 
acids. This peroxidation further releases peroxide radicals. This affects essential constituents 
of the cell membrane and might be involved in carcinogenesis/tumorigenesis.13 Because of 
the lipid peroxidation, there is a greater utilization of lipids including total cholesterol, 
lipoproteins and triglycerides for new membrane biogenesis. Cells fulfill these requirements 
either from circulation, by synthesis through the metabolism or from degradation of major 
lipoprotein fractions like VLDL, LDL or HDL. Earlier reports have shown that antioxidant 
vitamins have protective effects against lipid peroxidation.14-16 Lower blood lipids have been 
associated with various cancers.2,4,17,18 Furthermore, some investigators have also found 
relation of low serum cholesterol with increased risk of cancer occurrence19,20 and 
mortality.21,22 The plasma concentrations of lipids are not the single additive function of intake, 
utilization and biosynthesis because of its continuous cycling in and out of the blood stream. 
The question that whether hypolipidemia at the time of diagnosis, is a causative factor or is a 
result of cancer has remained unanswered.  
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Considering these curiosities, the present study was aimed to evaluate the plasma lipid profile 
including: (i) total cholesterol, (ii) LDL cholesterol (LDLC), (iii) HDL cholesterol (HDLC), (iv) 
VLDL cholesterol (VLDLC) and (v) triglycerides in head and neck cancer patients, patients 
with OPC and healthy individuals. The association between alterations in plasma lipid profile 
and habit of tobacco consumption was also studied.  
MATERIAL AND METHODS  
Subjects  
Fifty-two healthy individuals, who had no complaint or any major illness in recent past, were 
included in the study as controls. They were close relatives of the patients accompanying 
them during their hospitalization. One hundred fifty three patients with OPC were also 
included in the study from the Government Dental College and Hospital, Civil Hospital 
Campus, Ahmedabad. Out of these, 97 (63.4%) had oral submucous fibrosis, 44 (28.8%) had 
oral leukoplakia and 12 (7.8%) were with other diseases including dysplasia and verrucous 
hyperplasia. The hospital-based case control study included 184 untreated head and neck 
cancer patients, enrolled from the outpatients' department of the Gujarat Cancer and 
Research Institute, Ahmedabad. The patients were diagnosed as having cancer of oral cavity 
(n=121), pharynx (n=49), larynx (n=10) and maxilla (n=4). The diagnosis was based on 
clinical and histopathological examinations. Staging was done according to UICC 
classification.23 Table 1 provides clinicopathological details of cancer patients. Histologically, 
174 (94.6%) patients represented with squamous cell carcinoma. Twenty-eight patients had 
early disease (stage I and II) and 131 had advanced disease (stage III and IV). The 
classification according to their histological grade revealed that 64 patients had well 
differentiated, 85 had moderately differentiated, 20 had poorly differentiated and 5 had 
undifferentiated carcinoma.  
The subjects in each group were further classified into as having no habit of tobacco 
consumption (NHT) and with habit of tobacco consumption (WHT).  
Blood sample collection  
Fasting blood samples were collected from the subjects, into EDTA containing vacuettes. 
Samples were centrifuged; plasma was collected and stored at 800C until analyzed.  
METHODS  
Plasma cholesterol levels were estimated using cholesterol kits obtained from Autospan 
Reagents, Span Diagnostics (Gujarat, India). Briefly, 5 µl of plasma sample was mixed with 
500 µl of working reagent that contained cholesterol oxidase, cholesterol esterase, 
peroxidase, 4-amino phenanzone, surfactant, phenol, buffer, preservatives and stabilizer. The 
mixture was incubated at 370C for 10 minutes and absorbance was read at 505 nm.  
Plasma HDL cholesterol levels were also estimated using Autospan kits obtained from Span 
diagnostics (Gujarat, India). Briefly, 0.3 ml plasma sample was mixed with 0.3 ml precipitating 
reagent (PEG 6000, stabilizer and preservative), followed by 10 minutes incubation at room 
temperature. The mixture was centrifuged at 2000 rpm for 15 minutes. The supernatant 
obtained was mixed with working cholesterol reagent. After incubation of 10 minutes at 370C, 
absorbance was read at 505 nm.  
The triglyceride levels were estimated using liquid gold kits, obtained from Autospan 
reagents, Span diagnostics (Gujarat, India). Briefly, 10 µl plasma sample was mixed with 
1000 µl of triglycerides assay reagent containing Pipes buffer, lipase, 4chlorophenol, 
Magnesium ion, ATP, lipase, peroxidase, glycerol kinase, sodium azide, 4amino antipyrene, 
glycerol-3-phosphate oxidase and detergents. The mixture was then incubated for 10 minutes 
at 370C and absorbance was read at 505 nm. VLDLC and LDLC levels were calculated as 
shown below:  
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VLDLC = Triglycerides/5  
LDLC = Total Cholesterol (VLDLC) (HDLC)  
STATISTICAL ANALYSIS  
Student's t-test was performed to compare mean values of the parameters. "P" value <0.05 
was considered to be statistically significant. Results  
Habit of tobacco consumption in the subjects  
Habit of tobacco consumption in one or the other form (smoking/chewing/snuff) is highly 
prevalent in this region. As depicted in Figure 1, 95.4% of the patients with OPC and 85.8% of 
the cancer patients were consuming tobacco in one or the other form. The details regarding 
habit of tobacco consumption are provided in Table 2. Tobacco chewing in the form of readily 
available pouch (gutkha) and/or with lime was common in the patients with OPC and bidi 
(country cigarette) smoking among the cancer patients. Habit of tobacco snuff (oral/nasal) 
was usually observed in the female subjects, especially in female cancer patients. Use of 
tobacco, on an average, was greater than 10 years in all the subjects. 79/107 (73.8%) of the 
smokers in cancer patients and 34/66 (51.5%) of the smokers in patients with OPC had habit 
of smoking for more than 20 years. While, 29/72 (40.3%) of the tobacco chewers in cancer 
patients had habit of chewing for more than 20 years.  
Plasma lipid profile in the patients at the time of diagnosis  
The mean plasma lipid profile of controls and patients, at the time of diagnosis, are 
represented in Figure 2. A significant decrease in plasma total cholesterol and HDLC were 
observed in cancer patients (P=0.008 and P=0.000, respectively) as well as in patients with 
OPC (P=0.014 and P=0.000, respectively) as compared to the controls. However, the mean 
plasma levels of total cholesterol and HDLC were comparable between patients with OPC 
and cancer patients. The VLDLC and triglycerides levels were lower in cancer patients as 
compared to the controls (P=0.059) as well as the patients with OPC (0.04). However, plasma 
levels of VLDLC and triglycerides were comparable between controls and patients with OPC. 
Plasma LDLC levels did not reveal any significant difference among all three groups.  
Plasma lipid status in NHT and WHT subjects  
Further, we compared plasma lipid levels between NHT and WHT subjects (Table 3). First, 
the plasma lipid levels between tobacco consumers and non-consumers of the control group 
were compared. The controls consuming tobacco showed lower mean plasma lipid levels 
than the non-consumers. Secondly, the plasma lipid levels in tobacco habituates with OPC 
and cancer were also compared with the controls. Total cholesterol levels were significantly 
lower in WHT subjects with cancer (P=0.02) and OPC (P=0.01) as compared to the NHT. 
Likewise, HDLC levels were decreased in WHT subjects with cancer (P=0.001) and OPC 
(P=0.01) as compared to the NHT. Significantly low level of HDLC in patients with OPC and 
cancer patients as compared to controls (both NHT and WHT) (Table 3). When subjects were 
further categorized into above and below cutoff level (considering median of NHT as cut off), 
it was found that greater proportion of the subjects with OPC and cancer were having total 
cholesterol, HDLC,VLDLC and triglyceride levels below cutoff limit (Figure 3)  
DISCUSSION  
Cholesterol and triglycerides, important lipid constituents of cell, are essential to carry out 
several vital physiological functions. Cholesterol is essential for maintenance of the structural 
and functional integrity of all biological membranes. It is also involved in the activity of 
membrane bound enzymes and is important for stabilization of DNA helix.24 Cellular uptake 
and regulation of cholesterol is mediated by lipoprotein receptors especially located on the 
surface of the cells. For transport in plasma, triglycerides and cholesterol are packaged into 
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lipoproteins, which are then taken up and degraded by cells to fulfill demands for cellular 
functions.  
In some malignant diseases, blood cholesterol undergoes early and significant changes. Low 
levels of cholesterol in the proliferating tissues and in blood compartments could be due to the 
process of carcinogenesis. The question arises whether hypolipidemia is a predisposing 
factor or result of cancer? However, earlier studies have reported that hypolipidemia may 
result due to the direct lipid lowering effect of tumor cells or some secondary malfunction of 
the lipid metabolism or secondary to antioxidant vitamins.21,25-29 Several prospective and 
retrospective studies have shown an inverse association between blood lipid profile and 
different cancers.2,4,17,18,30 Schatzkin et al1 and Chyou et al8 have observed an inverse trend 
between lower serum cholesterol and head neck as well as esophageal cancers. The results 
are strengthened by the present study showing lower plasma total cholesterol, HDLC, VLDLC 
and triglycerides in head and neck cancer patients and patients with OPC than the healthy 
individuals.  
Cholesterol is an essential constituent of lipoprotein fractions like LDL, HDL and VLDL. 
Seventy five percent of the plasma cholesterol is transported in the form of LDLC. Body cells 
sequester cholesterol from LDL fraction of lipoproteins. LDL receptors are necessary for 
metabolizing circulating LDLC levels and nearly 80% of the plasma LDLC is cleared by LDL 
receptors.31 High activity of LDL receptors attributes for lowering the serum cholesterol levels. 
The individuals having deficient or defective LDL receptors remove plasma LDLC at much 
lower rate and have considerably elevated levels.32 In the present study, a significant 
decrease was observed in plasma HDLC in cancer patients. This is in accordance with 
previous reports, that low HDLC is an additional predictor of cancer2,30,33 and it might be a 
consequence of disease that is mediated by utilization of cholesterol for membrane 
biogenesis. We observed significantly decreased VLDLC and triglyceride levels in cancer 
patients as compared to the controls and patients with OPC. Alexopoulos et al18 have found 
non-significant difference in serum triglycerides between controls and patients. While others 
have observed elevated triglycerides levels in cancer patients.2,34  
Lipid peroxidation is an essential biochemical process that involves the oxidation of 
polyunsaturated fatty acids, the important components of cell membranes. Tobacco 
carcinogens generate reactive oxygen species and lipid peroxides, leading to tissue injury 
due to elevated lipid peroxidation, further damaging the cellular structural blocks like lipids, 
proteins, DNA etc. Thus, lipid peroxidation may play a role in endogenous formation of 
exocyclic DNA adducts. In our study, about 95% of the patients with OPC and 85% of the 
cancer patients were tobacco consumers. Therefore, levels of the lipids in WHT subjects in 
patients with OPC and cancer patients were compared with plasma lipid profile of NHT group 
of controls. Higher plasma cholesterol, HDLC, VLDLC and triglycerides were observed in 
controls without habit of tobacco consumption than controls and patients with tobacco habits. 
Earlier studies have shown an inverse relation between cholesterol and tobacco related 
cancers.1,20 Neufeld et al35 have reported passive smoking as a significant risk factor for 
decreased HDLC. Animal studies have shown that nicotine, a known tobacco carcinogen, 
affects activity of enzymes responsible for lipid metabolism.36 It is also reported that LDLC 
uptake and cholesterol biosynthesis were decreased in the liver of tumor bearing animals.23 
Further, exposure to tobacco carcinogens hampers antioxidant defense, leading to 
accelerated lipid peroxidation. There is a strong relationship between vitamin E (a liposoluble 
antioxidant vitamin) and lipids, especially cholesterol. Vitamin E is co-transported with all 
forms of cholesterol and contributes to the first line of defense against lipid peroxidation.14 
Further, triglycerides and cholesterol are positively correlated with vitamins.37 We observed a 
significant decrease in plasma levels of fat-soluble antioxidant vitamins such as vitamin E and 
b-carotene in tobacco habitués.38 Together, our study shows declined plasma levels of total 
cholesterol, HDLC, LDLC, VLDLC and triglycerides. As majority of the patients with OPC and 
cancer patients were with habit of tobacco, marker levels in NHT controls were compared with 
WHT controls, patients with OPC and cancer patients with habit of tobacco to eliminate any 
bias due to tobacco habit. To establish a cutoff of circulating marker level equal numbers of 
controls with and without habit of tobacco were enrolled. From the present study we can't 
predict the incidence of tobacco habitués in healthy population.  
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In conclusion, Rose et al39 reported 66% higher mortality rate due to cancer in the group of 
cancer patients with lowest plasma cholesterol than in the highest plasma cholesterol. Our 
results add to this evidence of an inverse relationship between lower plasma lipid profile and 
head and neck malignancies and oral precancerous conditions. The lower plasma lipid status 
may be a useful indicator for initial changes occurring in neoplastic cells. However, a detailed 
study of cholesterol carrying lipoprotein transport and the efficiency of the receptor system 
may help in understanding the underlying mechanisms of regulation of plasma cholesterol 
concentrations in cancer. Further work on these interesting results as well as in-depth studies 
on lipoprotein transport and receptor system is in progress in our laboratory.  
ACKNOWLEDGEMENTS  
 
